News

---

Nexilico, a pioneer in precision microbiome engineering, and Siolta Therapeutics have entered into a collaboration agreement to address necrotizing enterocolitis (NEC) using innovative microbial therapeutics.

Nexilico joins an elite group of startups leveraging AI to solve some of the world's most challenging problems, underscoring Nexilico's mission to harness the power of the microbiome for improving human health.

Nexilico has been awarded a grant from the National Institues of Health (NIH) to develop a novel microbiome-based solution to protect human health from the harmful effects of xenobiotic compounds.

Nexilico has been awarded $1M in funding from the NSF to develop an AI-driven  discovery platform for development of microbiome therapeutics for a

variety of indications. 

Wyatt is an established computational biologist with more than 15 years of experience in development of a variety of microbiome technologies in multiple academic and industrial positions.

  Nexilico and collaborators are awarded a grant to develop a new computational solution for reliable and cost-effective prediction of gut microbiome-mediated drug metabolism and its effect on drug efficacy and toxicity.  

Nexilico's collaboration with Microvi Biotech Inc. on developing precision biological processes receives a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant for $1.12M.

Nexilico, Inc. is selected by the National Institutes of Health, as one of the NIH SBIR awardees to exhibit  their technology at the upcoming Biotechnology Innovation Organization (BIO) International Convention.

Nexilico, Inc. has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $225,000 to conduct R&D work on the personalization of gut microbiome therapeutics.

Nexilico was selected to receive a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grant for $225,000 to develop a predictive  platform for gut microbiome precision medicine.